Calando Pharmaceuticals to Present at 19th Annual
Oppenheimer Healthcare Conference on November 4, 2008
Calando Pharmaceuticals, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today that its CEO, Dr. James Hamilton, will present at the 19th Annual Oppenheimer Healthcare Conference on Tuesday, November 4, 2008 at 11:00am ET. The conference is being held at the Waldorf Astoria Hotel in New York City. Dr. Hamilton's presentation will discuss Calando's proprietary delivery systems for siRNA and small molecule drugs and Calando's clinical program for its two lead compounds, CALAA-01 and IT-101.
CALAA-01, currently undergoing a Phase I clinical trial, is believed to be the first siRNA therapeutic to enter the oncology clinic. To our knowledge, it is also the first systemically delivered siRNA therapeutic formulated with a targeted delivery system. Calando's RONDEL(TM) delivery system was developed to address the long-standing obstacle of effective delivery and targeting for this potentially revolutionary new class of pharmaceuticals. CALAA-01 is a targeted nanoparticle comprised of a patented, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase, a clinically-validated cancer target and the RONDEL system.
IT-101, Calando's lead candidate delivering a small molecule drug, began clinical trials in 2006. IT-101 demonstrated safety and favorable pharmacokinetic properties in Phase I clinical trials and is currently undergoing a Phase II clinical trial. IT-101 is a conjugate of Cyclosert(TM), Calando's proprietary delivery system for small molecule drugs, and camptothecin. Both RONDEL(TM) and Cyclosert(TM) utilize modified cyclodextrin molecules to create an entirely new class of drug delivery materials, which Calando believes have the ability to solve many of the deficiencies observed in therapeutic product candidates.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statement on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.